NCT06472128Recruiting
Novel Digital Application for Patients With Acute Leukemia
Multi-Site Randomized Controlled Trial of a Novel Digital Application (DREAMLAND) to Improve Outcomes for Patients With Acute Myeloid Leukemia
Source: ClinicalTrials.gov · Last updated 10 Nov 2025
Brief summary (registry, in English)
This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 9 Jun 2024
- Start date
- 21 Oct 2024
- Primary completion date
- 30 Apr 2029
- Lead sponsor
- Massachusetts General Hospital
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT06472128
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 21 Oct 2024 to the primary completion date, 30 Apr 2029
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with acute or unstable psychiatric or cognitive conditions which the treating clinicians believes prohibits informed consent or compliance with study procedures.
Other
- Patients with a diagnosis of acute promyelocytic leukemia
Who the study is looking for
- Hospitalized patients (age \> 18 years) with a diagnosis of AML.
- Initiating treatment with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen or b) hypomethylating agents (HMA) +/- additional agents or modification of this regimen on a clinical trial.
- Ability to comprehend and speak English as the digital apps are only available in English
- Note: Patients newly diagnosed as well as those with relapsed/refractory AML initiating treatment with intensive or HMA-based chemotherapy will be eligible to participate.
Age in the registry: 18 years to 120 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts General Hospital (MGH) Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
| Duke University Coordinator of this site? Confirm its status | Durham | United States | Not yet recruiting |
| Fred Hutchinson Cancer Research Center (FHCRC) Coordinator of this site? Confirm its status | Seattle | United States | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.